Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.

Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts. - Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012044

Enrollment

Registered

2013-10-16

Start date

2013-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Simple giant hepatic cysts

Interventions

We will perform puncture, drainage and MINO injection therapy for patients of hepatic cysts.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients who have never received this treatment before -Patients who satisfy at least one of the following conditions; a. Patients who have abdominal distension b. Patients who have prominent tendency to large in cyst size c. Patients who have liver dysfunction d. Patients who have bleeding and infection in hepatic cysts e. Patients who have risk of hepatic cyst rupture f. Patients who have acute abdomen due to torsion g. Patients who have dilatation of bile ducts -Patients who require this treatment instead of the alternative treatment such as surgery -Patients from whom consent has been obtained to participate in this study, which has been approved by the ethics committee

Exclusion criteria

Exclusion criteria: a. Patients who have malignant tumors. b. Patients who have multiple hepatic cysts congenitally such as polycystic kidney disease. c. Patients whose cysts are connected to vessels and bile ducts d. Patients who have more serious disease compared to simple giant hepatic cysts.

Design outcomes

Primary

Measure	Time frame
The primary outcome is to research the recurrence rate of simple giant hepatic cysts. The recurrence case is defined as follows; -Patients who have abdominal distension -Patients who have prominent tendency to large in cyst size -Patients who have liver dysfunction -Patients who have bleeding and infection in hepatic cysts -Patients who have risk of hepatic cyst rupture -Patients who have acute abdomen due to torsion -Patients who have dilatation of bile ducts The recurrence rate will be calculated as accumulated recurrence rate for 3 years.	—

Measure

Time frame

The primary outcome is to research the recurrence rate of simple giant hepatic cysts. The recurrence case is defined as follows; -Patients who have abdominal distension -Patients who have prominent tendency to large in cyst size -Patients who have liver dysfunction -Patients who have bleeding and infection in hepatic cysts -Patients who have risk of hepatic cyst rupture -Patients who have acute abdomen due to torsion -Patients who have dilatation of bile ducts The recurrence rate will be calculated as accumulated recurrence rate for 3 years.

—

Secondary

Measure	Time frame
The secondary outcome is reduction rate of cysts at each evaluation period. The reduction rate will be calculated by cyst volume based on CT results comparing at the time of pre-treatment to post- treatment. We will evaluate the changes in symptoms between pre-treatment and post-treatment.	—

Countries

Japan

Contacts

Public ContactYuichi Nozaki

National Center for Global Health and Medicine Department of Gastroenterology

ynozaki@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026